ERBB2 and cervical carcinoma: Neratinib, an ERBB2 inhibitor, showed a confirmed objective response rate of 25% and progression-free survival of 7.0 months in 10 cervical carcinoma patients from the phase 2 SUMMIT basket trial (31).